Shares of Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) traded down 3.5% on Thursday . The company traded as low as $5.75 and last traded at $5.85, with a volume of 1,866,732 shares traded. The stock had previously closed at $6.06.

A number of analysts have recently weighed in on the company. Brean Capital reissued a “buy” rating on shares of Progenics Pharmaceuticals in a research report on Wednesday, June 15th. Needham & Company LLC reissued a “buy” rating and issued a $11.00 price objective on shares of Progenics Pharmaceuticals in a research report on Friday, July 22nd. BTIG Research reissued a “buy” rating and issued a $9.00 price objective on shares of Progenics Pharmaceuticals in a research report on Wednesday, July 20th. Jefferies Group reissued a “buy” rating and issued a $9.00 price objective on shares of Progenics Pharmaceuticals in a research report on Wednesday, April 6th. Finally, Zacks Investment Research raised Progenics Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, July 7th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $9.95.

The stock’s market capitalization is $406.39 million. The company has a 50 day moving average price of $5.01 and a 200 day moving average price of $4.72.

Progenics Pharmaceuticals (NASDAQ:PGNX) last released its quarterly earnings results on Thursday, May 5th. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by $0.05. During the same quarter last year, the business earned ($0.15) EPS. The business earned $2.50 million during the quarter, compared to the consensus estimate of $3.27 million. The firm’s quarterly revenue was up 908.1% compared to the same quarter last year. Equities analysts forecast that Progenics Pharmaceuticals Inc. will post $0.12 earnings per share for the current year.

Progenics Pharmaceuticals, Inc is engaged in developing medicines and other products for targeting and treating cancer. The Company’s products in development include therapeutic agents designed to target cancer and imaging agents, which focuses on enabling clinicians and patients to accurately visualize and manage their diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.